The present study demonstrated that treating cervical cancer cells with topotecan caused increased levels of cells death, which was associated with increasing levels of active pERK1/2, thereby suggesting that topotecan-promoted cells death was at least partially mediated by the activation of DAPK1 via ERK1/2 activity. Here, MAPK3 is linked to cervical cancer.